{"id":"W4386631299","doi":"10.1016/s1470-2045(23)00382-0","title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Genentech; EMD Serono; Bavarian Nordic; Astellas Pharma; Sanofi; Exelixis; Advanced Accelerator Applications; Endocyte; Janssen Pharmaceuticals; Invitae; Gilead Sciences; Merck; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ipsen; BeiGene; Constellation Pharmaceuticals","keywords":"Abiraterone; Prostate cancer; Medicine; Placebo; Olaparib; Urology; Abiraterone acetate; Internal medicine; Oncology; Double blind; Androgen deprivation therapy; Cancer; Androgen receptor; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002696805,0.0003408513,0.001505508,0.0002748669,0.0001328418,0.00004674933,0.0003219721,0.0001556566,0.0001660518],"category_scores_gemma":[0.0001996636,0.0002157888,0.0001412216,0.0006676549,0.000371499,0.0001299223,0.0001253242,0.0005805042,0.00005819055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009975213,"about_ca_system_score_gemma":0.002321818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001916812,"about_ca_topic_score_gemma":0.004147599,"domain_scores_codex":[0.9961023,0.0007624847,0.001046533,0.000558023,0.0006314224,0.0008992195],"domain_scores_gemma":[0.9976671,0.0009552161,0.0004112541,0.0005834706,0.0002135989,0.0001694088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9770636,0.0006104671,0.00002451488,0.0002322592,0.0005565541,0.000659377,0.002993905,0.001049377,0.0109526,0.0001362533,0.003796084,0.001925003],"study_design_scores_gemma":[0.9807305,0.007133269,0.0004634112,0.0001315324,0.0003132902,0.00001100784,0.0005106415,0.001203604,0.004080847,0.00008565359,0.005126976,0.0002092264],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980681,0.0006786395,0.0000064121,0.007153179,0.001106627,0.0072149,0.000429187,0.00008702447,0.002643015],"genre_scores_gemma":[0.9869397,0.001696759,0.0001082739,0.00008642759,0.0008448023,0.002483095,0.0005420058,0.00005345311,0.007245477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007066752,"threshold_uncertainty_score":0.879961,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.313893449351758,"score_gpt":0.459480059444977,"score_spread":0.145586610093219,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}